AB0116 EVALUATING THE IMPACT OF METFORMIN TARGETS ON THE RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS: A MENDELIAN RANDOMIZATION STUDY
L. L. Zheng,Y. X. Chen,C. Wang,M. J. Chang,S. X. Zhang,Q. Yu,P. F. He
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.2355
IF: 27.973
2023-01-01
Annals of the Rheumatic Diseases
Abstract:Background Metformin is a biguanide oral hypoglycemic agent that is widely used as a first-line drug treatment for type II diabetes. In addition, metformin is also used in the treatment of certain autoimmune diseases, such as systemic lupus erythematosus (SLE). It plays a key role in the pathogenesis of SLE through pathways such as inhibiting type 1 IFN, regulating T effector cells and proinflammatory cytokines[1]. However, the causal relationship of the metformin-related targets on the risk of SLE is still unclear. Objectives The purpose of this study was to assess the causal effect of metformin targets (AMPK, MCI, MG3, GDF 15 and GLP 1/ GCG) on the risk of SLE using Mendelian randomization (MR). Methods Genetic variants including downstream and 100 kb upstream of encoding five genes were selected as candidate tool variants. The SNP was further screened as in low linkage disequilibrium (r2 < 0.3) and associated with HbA 1 c (P ≤ 0.05). The Genome-wide association study (GWAS) of HbA 1 c comes from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (n = 88,355)[2]. The SLE data (ncase = 5,201, ncontrol = 9,066) are pooled from publicly available GWAS. Two-sample MR was performed using inverse variance weighted (IVW), MR-Egger, and weighted median (WM) to obtain causal estimates of metformin-related targets and risk of SLE. In addition, sensitivity analysis, outlier (MR-PRESSO) and leave-one-out analysis were conducted to test the heterogeneity and level pleiotropy of the results. Results Genetically predicted increase in HbA1c instrumented by GDF 15 variants was associated with increased risk of SLE (GDF 15[p = 0.028]). However, genetically predicted AMPK, MG3, MCI, and GLP 1/ GCG were not associated with SLE risk (AMPK [p = 0.122], MG3 [p = 0.105], MCI [p = 0.762], GLP 1/ GCG [p = 0.361]) (Figure 1). No outlier between GDF 15 and the risk of SLE was identified via the MR-PRESSO test. The leave-one-out analysis verified the robustness of the outcomes. Conclusion This study suggests that the GDF 15 gene may be a plausible mechanism of action to reduce the risk of SLE and provides critical evidence to guide future clinical trials of metformin. References [1]Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease. Korean J Intern Med 2022; 37(1):13-26. [2]Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med 2017; 14(9):e1002383. Acknowledgements: NIL. Disclosure of Interests None Declared.